Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedJul 03, 2026
DataAggregated Company Financials
Companies1405
  • 7D5.0%
  • 3M13.3%
  • 1Y23.7%
  • YTD6.9%

Over the last 7 days, the Healthcare industry has risen 5.0%, driven by gains from Eli Lilly of 7.6%. This means that the industry has gained 24% over the past year. As for the next few years, earnings are expected to grow by 18% per annum.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Jul 2026US$6.9tUS$3.3tUS$122.0b25.8x56.3x2.1x
Sun, 31 May 2026US$6.4tUS$3.3tUS$122.4b23.2x52.2x1.9x
Tue, 28 Apr 2026US$6.1tUS$3.3tUS$121.4b23.6x50.6x1.9x
Thu, 26 Mar 2026US$6.1tUS$3.3tUS$124.9b22.7x48.6x1.9x
Sat, 21 Feb 2026US$6.6tUS$3.3tUS$128.1b26.6x51.4x2x
Mon, 19 Jan 2026US$6.5tUS$3.2tUS$136.3b27.3x48x2x
Wed, 17 Dec 2025US$6.5tUS$3.2tUS$135.3b26.3x48.1x2x
Fri, 14 Nov 2025US$6.3tUS$3.2tUS$133.4b26x47.2x2x
Sun, 12 Oct 2025US$5.9tUS$3.1tUS$137.9b24.5x42.9x1.9x
Tue, 09 Sep 2025US$5.7tUS$3.1tUS$137.6b23.1x41.7x1.9x
Thu, 07 Aug 2025US$5.5tUS$3.1tUS$134.9b22.8x40.5x1.8x
Sat, 05 Jul 2025US$5.6tUS$3.0tUS$127.9b24.3x43.4x1.8x
Mon, 02 Jun 2025US$5.4tUS$3.0tUS$127.6b23.1x42.2x1.8x
Wed, 30 Apr 2025US$5.4tUS$2.7tUS$116.9b24.9x46.3x2x
Fri, 28 Mar 2025US$5.7tUS$2.6tUS$81.6b26.3x69.4x2.1x
Sun, 23 Feb 2025US$5.8tUS$2.6tUS$80.5b26.6x72.4x2.2x
Tue, 21 Jan 2025US$5.9tUS$2.9tUS$78.9b27.7x74.2x2x
Thu, 19 Dec 2024US$5.8tUS$2.9tUS$78.1b27.5x74.7x2x
Sat, 16 Nov 2024US$6.1tUS$2.9tUS$76.6b27.8x79.3x2.1x
Mon, 14 Oct 2024US$6.2tUS$2.8tUS$60.0b29.8x104x2.2x
Wed, 11 Sep 2024US$6.2tUS$2.8tUS$60.4b30.1x103.2x2.2x
Fri, 09 Aug 2024US$6.2tUS$2.9tUS$59.6b30.3x103.4x2.1x
Sun, 07 Jul 2024US$6.1tUS$2.8tUS$62.2b30.2x98.5x2.2x
Tue, 04 Jun 2024US$6.1tUS$2.8tUS$64.0b30.5x95.2x2.2x
Thu, 02 May 2024US$6.0tUS$2.8tUS$71.2b31.2x84.3x2.1x
Sat, 30 Mar 2024US$6.4tUS$2.8tUS$82.8b32.4x76.8x2.3x
Mon, 26 Feb 2024US$6.3tUS$2.8tUS$85.5b31.1x74x2.3x
Wed, 24 Jan 2024US$6.4tUS$2.8tUS$90.1b32.7x70.5x2.3x
Fri, 22 Dec 2023US$6.0tUS$2.8tUS$91.5b32.3x66.1x2.1x
Sun, 19 Nov 2023US$5.8tUS$2.8tUS$90.7b27.8x63.6x2x
Tue, 17 Oct 2023US$5.9tUS$2.8tUS$98.9b26.4x59.7x2.1x
Thu, 14 Sep 2023US$6.0tUS$2.8tUS$98.7b27.8x61.3x2.2x
Sat, 12 Aug 2023US$6.2tUS$2.8tUS$99.1b28.6x62.6x2.2x
Mon, 10 Jul 2023US$5.9tUS$2.7tUS$110.3b26x53.1x2.1x
Price to Earnings Ratio

53.1x


Total Market Cap: US$5.9tTotal Earnings: US$110.3bTotal Revenue: US$2.7tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 56.3x which is lower than its 3-year average PE of 65.4x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 3.4% per year over the last three years.
  • Revenues for these companies have grown 6.9% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market1.38%
Healthcare4.96%
Healthtech15.33%
Pharma6.06%
Biotech5.36%
Healthcare Services3.90%
Medical Equipment3.67%
Life Sciences3.17%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 56.1x.
    • Analysts are expecting annual earnings growth of 17.0%, which is higher than its past year's earnings growth of 5.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 25% over the next 5 years.
  • However this is lower than its past earnings growth rate of 55% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 14% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$1.21k7.6%
+US$76.9b		55.5%PE42.8x
JNJ Johnson & JohnsonUS$263.047.4%
+US$43.7b		68.6%PE30.1x
ABBV AbbVieUS$261.077.4%
+US$31.7b		37.9%PE128.3x
VRTX Vertex PharmaceuticalsUS$528.0410.0%
+US$12.1b		14.9%PE30.9x
AMGN AmgenUS$374.156.0%
+US$11.5b		25.5%PE25.9x

Latest News

VRTX
US$528.04
Vertex Pharmaceuticals
7D
10.0%
1Y
14.9%
UNH
US$425.36
UnitedHealth Group
7D
2.4%
1Y
37.9%
ABBV
US$261.07
AbbVie
7D
7.4%
1Y
37.9%
RGC
US$6.37
Regencell Bioscience Holdings
7D
-15.0%
1Y
-72.3%
MRK
US$129.56
Merck
7D
3.3%
1Y
60.1%
Seeking Alpha • 23h

Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up

Summary Merck & Co., Inc. is fairly valued after a strong YTD rally, with momentum in Keytruda and Winrevair driving raised guidance. Keytruda's patent cliff in 2028 remains a pivotal risk, but MRK is leveraging lifecycle management and pipeline assets to offset erosion. DCF modeling at 4% CAGR and 21% FCF margin supports a Hold rating for MRK stock, with intrinsic value resilient even under moderate downside scenarios. Execution on Winrevair, Keytruda Qlex, and the anti-TL1A IBD asset are critical for sustaining growth and valuation. Read the full article on Seeking Alpha
JNJ
US$263.04
Johnson & Johnson
7D
7.4%
1Y
68.6%
QURE
US$41.81
uniQure
7D
-14.8%
1Y
189.9%
Narrative Update • Jul 02

QURE: FDA Reversal And 2026 BLA Plan Will Drive Huntington’s Outlook

Analysts have lifted the uniQure fair value estimate from about $52.56 to $64.47, citing recent FDA feedback on AMT-130 that, in their view, improves visibility on a potential accelerated approval path and supports higher modeled revenue growth with a lower assumed discount rate and P/E multiple. Analyst Commentary Recent Street research on uniQure has shifted sharply following the latest FDA Type B meeting on AMT-130, with multiple firms revising price targets and ratings after the company outlined plans for a potential accelerated approval filing.
AMGN
US$374.15
Amgen
7D
6.0%
1Y
25.5%
A
US$130.69
Agilent Technologies
7D
-3.6%
1Y
7.7%
LLY
US$1,213.91
Eli Lilly
7D
7.6%
1Y
55.5%
ZTS
US$74.80
Zoetis
7D
-3.9%
1Y
-53.0%
EVMN
US$12.96
Evommune
7D
-46.3%
1Y
n/a
ZBH
US$87.47
Zimmer Biomet Holdings
7D
-3.8%
1Y
-6.6%
HTFL
US$27.97
HeartFlow
7D
-20.1%
1Y
n/a
ISRG
US$426.01
Intuitive Surgical
7D
5.3%
1Y
-21.8%
GMED
US$80.12
Globus Medical
7D
-5.4%
1Y
35.4%
Narrative Update • Jun 25

GMED: EPS Upside And Robotics Progress Will Balance Execution And Margin Risks

Globus Medical's analyst price target has moved by $2.82 as analysts weigh fresh evidence around slightly lower modeled revenue growth, higher projected profit margins, and a revised future P/E assumption following recent mixed target changes from Needham and Wells Fargo. Analyst Commentary Recent research commentary on Globus Medical reflects a mixed but cautious tone, as price targets are fine tuned around updated assumptions for revenue growth, profitability and the appropriate P/E range for the stock.